Pharmacogenetics, Emotional Reactivity and Smoking
Status:
Completed
Trial end date:
2019-12-18
Target enrollment:
Participant gender:
Summary
The goals of this placebo-controlled randomized clinical trial were to evaluate the
differences in emotional reactivity (peak startle response to affective stimuli) during a
cessation attempt among smokers treated with bupropion, varenicline, or placebo, and to
determine if these differences were moderated by genotype.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
National Institute on Drug Abuse (NIDA) National Institutes of Health (NIH)